Navigation Links
Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
Date:11/13/2008

EAST BRUNSWICK, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Christopher Clement, President and Chief Executive Officer of Savient Pharmaceuticals will present a corporate update at the upcoming Lazard Capital Markets 5th Annual Healthcare Conference.

The presentation is scheduled to begin on Tuesday, November 18, 2008 at 9:25 a.m. ET. The Conference will be held at the St. Regis Hotel in New York City November 18-19, 2008.

Individuals can listen to a live webcast of the presentation by logging on to the Investor Relations section of Savient Pharmaceuticals' web site, http://www.savient.com. A replay of the webcast will be available on the company's web site for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, pegloticase for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; and the Phase 3 clinical studies were completed in October 2007 and the BLA was filed with the FDA in October 2008. Savient has exclusively licensed worldwide rights to the technology related to pegloticase, formerly referred to as Puricase(R), from Duke University and Mountain View Pharmaceuticals, Inc. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further information on Savient can be accessed by visiting: http://www.savient.com.

SVNT-G

Contact:

Mary Coleman

Director, Investor Relations

Savient Pharmaceuticals, Inc.

information@savient.com

(732) 418-9300


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
2. Savient Submits Biologics License Application (BLA) for pegloticase
3. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
4. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
5. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
6. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
7. Memory Pharmaceuticals Reports Third Quarter 2008 Financial Results
8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
9. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
10. Nventa Biopharmaceuticals Announces Third Quarter 2008 Financial Results and Recent Corporate Highlights
11. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... CA (PRWEB) , ... September 20, 2017 , ... ... interest organization focused on molecular manufacturing and other transformative technologies, announced the winners ... for Experiment and the other for Theory in nanotechnology/molecular manufacturing. , Established in ...
(Date:9/19/2017)... ... September 19, 2017 , ... The latest generation ... step of sample prep for metals digestion—the addition of acids and reagents. The ... price. The system is ideal for any laboratory performing their own unique metals ...
(Date:9/19/2017)... ... September 19, 2017 , ... A best-selling author and an ... “Grit” author Angela Duckworth and her team at Character Lab have joined Philadelphia’s ... international law firm with decades of experience supporting high-growth companies in the technology ...
(Date:9/19/2017)... ... September 19, 2017 , ... The new and improved Oakton® ... pocket testers even stand upright with a new cap design that is versatile, functional ... the field who need to test water quality. , The Oakton pocket testers have ...
Breaking Biology Technology:
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
Breaking Biology News(10 mins):